Abstract
OBJECTIVES: To systematically analyse the effect of pharmacological treatment of hypertension (HTN) on cognitive decline in older adults. METHODS: Randomised, placebo-controlled trials with a prespecified quantitative outcome of cognition and a pharmacological intervention for at least 12 months to treat HTN in older adults (>60 years). Our primary outcome was change in cognition with pharmacological treatment of HTN. Standardised mean difference (SMD) was used to analyse different outcomes reported in the selected studies. We searched PubMed CENTRAL and the Cochrane Library from inception to 6 July 2020. Two independent reviewers assessed trial quality and extracted data. Internal and external validity of the studies was assessed. RESULTS: Nine randomised controlled trials with 34 994 participants were included in the final analysis. The net SMD for change in cognition was -0.049 (CI: -0.078 to -0.019) indicating that treatment of HTN decreased cognitive decline. Heterogeneity was low with an I² of 6%. DISCUSSION: Current evidence does not indicate worsening of cognition with treatment of HTN. Treatment of HTN in older adults may reduce cognitive decline. These results have important implications in clinical management of patients at risk for dementia. PROSPERO REGISTRATION NUMBER: CRD42020139750.